Covid 19 Research Clinical Trials by Shray Alag

D005764: Gastroesophageal Reflux

Developed by Shray Alag, The Harker School
Sections: Correlations, Clinical Trials, and HPO

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (4)

	Name (Synonyms)	Correlation
drug2054	IW-3718 Wiki	0.71
drug2866	None - NA Wiki	0.71
drug1475	Electronic questionnaire Wiki	0.50

	Name (Synonyms)	Correlation
drug5130	placebo Wiki	0.17

Correlated MeSH Terms (3)

	Name (Synonyms)	Correlation
D003108	Colonic Diseases NIH	0.71
D004942	Esophagitis, Peptic NIH	0.71
D004932	Esophageal and Gastric Varices NIH	0.71

Correlated HPO Terms (2)

	Name (Synonyms)	Correlation
HP:0002020	Gastroesophageal reflux HPO	1.00
HP:0002040	Esophageal varix HPO	0.71

Clinical Trials

Navigate: Correlations HPO

There are 2 clinical trials

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors

The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).

NCT03561090

Conditions

Gastroesophageal Reflux Disease (GERD)

Interventions

Drug: IW-3718
Drug: placebo

MeSH:Gastroesophageal Reflux Esophagitis, Peptic

HPO:Gastroesophageal reflux

Primary Outcomes

Measure: Proportion of Overall Heartburn Responders

Time: Week 8

Secondary Outcomes

Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3

Time: Week 8

Measure: Percent Change From Baseline to Week 8 in WHSS

Time: Baseline, Week 8

Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS)

Time: Baseline, Week 8

Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period

Time: up to Week 8

Measure: Proportion of Overall Regurgitation Responders

Time: Week 8

Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period

Time: Week 8

Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item

Time: Baseline, Week 8

Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period

Time: Week 8

Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period

Time: Week 8

Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders

Time: up to Week 8

Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness

Time: Baseline, Week 8

Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period

Time: up to Week 8

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital

The aim of this study is to evaluate patient and consultant experiences with phone consultations for endoscopy-related outpatient appointments during the COVID-19 outbreak.

NCT04344964

Conditions

Colon Polyp
Colon Disease
Reflux, Gastroesophageal
Varices, Esophageal

Interventions

Other: None - NA

MeSH:Colonic Diseases Gastroesophageal Reflux Esophageal and Gastric Varices

HPO:Esophageal varix Gastric varix Gastroesophageal reflux

Primary Outcomes

Description: percentage of patients that did not answer phone calls (at least 3 calls) or with documented FTA for the retrospective group.

Measure: Failed to attend patients

Time: 2 months

Secondary Outcomes

Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020 - MSF and PAT-VC questionnaires). These are mostly Likert-scale response mode statements.

Measure: Patient satisfaction with the phone consult

Time: 2 months

Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020). These are mostly Likert-scale response mode statements.

Measure: Consultant satisfaction with the phone consult

Time: 2 months

HPO Nodes

HP:0002020: Gastroesophageal reflux

Genes 495

CDKL5 TGIF1 PIGN SLC6A5 NOS1 DSP EEF1A2 TCF4 TOP3A CLTC PIEZO1 COL7A1 NODAL COL1A1 DHCR7 GTF2IRD1 NECAP1 ERCC6 CHAMP1 COL7A1 CNKSR2 ASXL1 SHH GABRG2 ARVCF RRM2B STAG1 SFTPA1 RPL10 MRPS34 CAV1 PACS1 RREB1 NALCN STXBP1 CTBP1 PIK3CD SNRPB CTHRC1 SEC63 RAD21 AARS1 EPB41L1 FGF8 GAS1 KCNQ5 FOXH1 CLIP2 ELN PHGDH HIRA GP1BB CCR6 BRSK2 ADAMTS2 IRF5 BRAF MEN1 ADNP DLL1 SEC24C SIX3 FOXG1 POLG2 ELN EXT2 SLC19A2 HCN1 NUP62 CLTC SATB2 PORCN FOXH1 GABRA5 TERC GRIN2B MECP2 AP3B1 CDON CUX1 SON MCEE ADAR NIPBL TRIP4 SLC1A2 GAS1 CRLF1 GABRB2 STAG1 GMNN KMT2A SLC25A24 NEDD4L COL5A1 CCR6 KDM5B BLM NTRK2 KNSTRN CDON PHOX2B CDK19 SLC5A7 SHH DISP1 SMC3 DDC NEPRO PIEZO2 ZIC2 NEXMIF NFIX ACTL6B COL13A1 ERCC8 ZMYND11 DISP1 CPLX1 SLC25A4 KCNB1 FOXH1 EEF1A2 CDH15 YWHAG SEMA3E TDGF1 HRAS SLC35A2 CACNG2 SLC6A3 SLC35A2 GLI2 FGF8 CDC6 SMG9 PPM1D FGFR1 CAV1 KIF1A PUF60 NRXN1 ELP1 TAF1 FGFRL1 KMT2A TAOK1 ORC4 ASCC1 ASCL1 PPP3CA DYNC1H1 ELP1 CAMK2A DISP1 DALRD3 STAG2 ARID2 ERMARD KCNA2 SIX3 KIF1A RAI1 SH2B1 STN1 LONP1 CHRNA3 TSPYL1 ZIC2 TIMM22 ASPA MECP2 KCNQ3 LAMA2 MAP1B GABRA2 TERT TRPM3 FBXL4 ASXL1 CAMTA1 DHCR7 TRMT10C FGF8 SFTPC ATP11A KIAA0586 SHH CNTNAP1 PAK1 CAMK2B SYNGAP1 AMER1 CREBBP UBA5 TWIST1 LBR NODAL AP3B2 SKI PTCH1 ZIC2 RAD21 NUS1 SOX5 ALMS1 SYT1 DLL1 RERE TRAPPC12 FGF12 CIC ATP7A DNM1 AFF4 DEAF1 COG7 ABCD4 KLHL7 CDON TYMP CDKN1B SLC13A5 FOXG1 CCN2 MAP3K7 HLA-DRB1 PTCH1 HLA-DQA1 GLI2 SLC1A4 SLC6A3 TCF4 AGRN CTCF NUP214 SCN8A POLG2 NIPBL WNK1 FLNA SET SLC18A3 FGFR1 RTEL1 RAI1 MYMK PCGF2 FLCN GALC DYRK1A ARNT2 FMR1 RHBDF2 VAMP1 CAMK2B GNB5 DDOST NONO CDKN2C PIGN CCDC47 ADAT3 MID1 SCN9A APC2 FGFR3 ASH1L FBN1 CNTNAP2 KIAA0319L PSPH CACNA1A SYT1 SLC46A1 NSD1 SLC2A10 SPOP PGM3 SMC1A MBD5 JMJD1C CREBBP SHANK3 TBX1 NRXN1 ATRX GEMIN4 TBL2 TBX1 PIGT CSNK2B WWOX ATRX SYNJ1 TSPYL1 FLNA PARN STXBP1 SYNGAP1 NEXMIF RFC2 SLC9A6 NSD2 POLR2A RRM2B LIMK1 CCN2 TWNK PDHA1 SIX3 EP300 ATP6V1A GLI2 ARV1 STAG2 SEC23A CDKN2B TBC1D24 LRP5 SZT2 LTBP4 MAP3K7 MUC5B MAGEL2 ATN1 CDON ARFGEF2 SRPX2 SSR4 SMC1A IQSEC2 PYCR1 DPP9 ARF1 CACNA1B ATRX PRDM16 ATAD1 DEAF1 ZIC2 AFF4 CLCN4 ADGRG1 ALDH18A1 STAC3 NPHS1 POGZ FOXH1 EXT2 ORC6 GRIN1 CHAMP1 GLRB LONP1 GRIN2D TMTC3 ALDH18A1 FGF8 RERE POLG TCF4 SKI TGIF1 HLA-DQB1 WAC POGZ SMC1A CHAT TDGF1 SEC31A SLC25A1 PTCH1 DOCK8 RPL10 RPL10 WDR26 MYT1L GLI2 GABRD ITCH GAS1 PPP3CA GAS1 EHMT1 CCDC22 SAMD9 PSAP EHMT1 DYRK1A TFAP2A UFD1 TGIF1 HNRNPH2 GTF2I MECP2 KAT6B EBF3 SHANK3 PI4KA MYO9A CYFIP2 KCNA2 PTCH1 COL13A1 TRAK1 UBA5 SETD5 TDGF1 ABCA3 ZSWIM6 CSPP1 MSL3 RAI1 MED12L PARS2 TGIF1 CHD7 SALL1 SMC1A SFTPA2 KIRREL3 FAM13A SETD2 KCNQ2 SKI NALCN OCRL DHDDS PRKCSH CREBBP TECPR2 SHROOM4 SMC3 HIVEP2 GPHN GLRA1 TDGF1 FARSB POLG FCSK RET RAB11A DLL1 HLA-DRB1 HIVEP2 SHH SIX3 RERE LETM1 TBX4 HDAC8 TCF4 STAG2 SYT2 CENPT WHCR ATRX MMP1 DDOST MAGEL2 MLXIPL ORC1 PIGN KMT2C FOXG1 CHMP1A MED12L RETREG1 RNF125 SCN3A NODAL SNAP25 ATP6 BAZ1B DLL1 MED12 CDKN1A COMT TERT HDAC8 USP7 KAT6A GRIN1 GNAS MEIS2 FLII COL5A2 WASHC5 IRF5 NODAL KCNAB2 NONO MSR1 DISP1

Protein Mutations 1

D961H

SNP 0

HPO

Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials

HPO Nodes

HP:0002020: Gastroesophageal reflux

Genes 495

Protein Mutations 1

D961H

SNP 0

Reports

Data processed on December 13, 2020.

An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.

Drug Reports MeSH Reports HPO Reports

Report Sections

See All Reports

D005764: Gastroesophageal Reflux

Correlations computed by analyzing all clinical trials.

Correlated Drug Terms (4)

Correlated MeSH Terms (3)

Correlated HPO Terms (2)

Clinical Trials

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors Click for details

NCT03561090

Conditions

Interventions

MeSH:Gastroesophageal Reflux Esophagitis, Peptic

HPO:Gastroesophageal reflux

Primary Outcomes

Secondary Outcomes

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital Click for details

NCT04344964

Conditions

Interventions

MeSH:Colonic Diseases Gastroesophageal Reflux Esophageal and Gastric Varices

HPO:Esophageal varix Gastric varix Gastroesophageal reflux

Primary Outcomes

Secondary Outcomes

HPO Nodes

Genes 495

Protein Mutations 1

SNP 0

HPO

HPO Nodes

Genes 495

Protein Mutations 1

SNP 0

Reports

1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors

2 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital